Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Summary
Grunert S et al.  
Intracoronary and Intravenous Magnesium Does Not Reduce Myocardial Infarct Size in a Canine Model of Regional Ischaemia and Reperfusion

Journal of Clinical and Basic Cardiology 2002; 5 (1): 23-28

PDF    Summary    Figures   

Fig. 1: Magnesium - intrakoronar - intravenös Fig. 2: Magnesium - Kalium - Serumkonzentration Fig. 3: Magnesium - Linksventrikulärer Druck Fig. 4: Magnesium-Kalium-Aspartat - Herzfrequenz Fig. 5A-B: Magnesium - Linksventrikulärer Druck Fig. 6: Magnesium - Infarktgröße



Keywords: HerzHundInfarktgrößeIschämiemagnesiumMyokardinfarktreperfusiondogheartinfarct sizeischaemiamagnesiummyocardial infarctionreperfusion

Clinical trials show controversial effects of magnesium infusion in patients with acute myocardial infarction. In LIMIT-2, intravenous magnesium lowered mortality, but in the much larger ISIS-4, intravenous magnesium had no effect. Because of these conflicting results, we tested two hypotheses in a dog model of ischaemia and reperfusion. A) Intracoronary magnesium infusion given in the early reperfusion period has a protective effect against myocardial reperfusion injury. B) Systemic magnesium-potassium infusion with doses comparable to those used in clinical studies, may reduce myocardial infarct size. Anaesthetized open chest dogs underwent 1 h of left anterior descending artery occlusion followed by 6 h of reperfusion. A) Animals received intracoronary magnesium aspartate (Mg i.c., n = 5) or vehicle infusion (Control i.c., n = 5) for the first hour of reperfusion to increase regional plasma concentration by 4 mmol l?1. B) Animals received intravenous magnesium-potassium-aspartate (Mg-K i.v., n = 6) or vehicle infusion (Control i.v., n = 8) beginning 1 h before occlusion until the end of the 6 h reperfusion period. Intracoronary magnesium had no influence on infarct size (Mg i.c. 20.6 ± 5.0 % of area at risk, Control i.c. 24.4 ± 8.7 % of area at risk, P = ns) or regional post-ischaemic wallfunction. Application of intravenous magnesium-potassium did not reduce myocardial infarct size (Mg-K i.v. 14.1 ± 14.8 %; Control i.v. 18.1 ± 12.2 % of area at risk; P = ns). The possible beneficial effect of magnesium infusion is probably not due to an early, direct protective effect on ischaemic-reperfused myocardium.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung